Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Southeast Henderson — Henderson, Nevada
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Nevada: - Carson Tahoe Regional Medical Center — Carson City, Nevada
- Cancer and Blood Specialists-Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
- OptumCare Cancer Care at Seven Hills — Henderson, Nevada
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Nevada: - OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
- Renown Regional Medical Center — Reno, Nevada
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Nevada: - OptumCare Cancer Care at Seven Hills — Henderson, Nevada
- OptumCare Cancer Care at Charleston — Las Vegas, Nevada
- Radiation Oncology Centers of Nevada Central — Las Vegas, Nevada
- Radiation Oncology Centers of Nevada Southeast — Las Vegas, Nevada
- OptumCare Cancer Care at MountainView — Las Vegas, Nevada
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Nevada: - Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Nevada: - Optum Care Cancer Center ( Site 0050) — Las Vegas, Nevada
- Renown Regional Medical Center ( Site 0041) — Reno, Nevada
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Nevada: - Renown Health Medical Oncology — Reno, Nevada
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Nevada: - Renown Regional Medical Centre — Reno, Nevada
- Cancer Care Specialists — Reno, Nevada
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Nevada: - Cancer Care Specialists — Reno, Nevada
Phase 1 Recruiting Industry
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT05216432
Sites in Nevada: - Renown Regional Medical Center — Reno, Nevada